Case File
efta-efta01121458DOJ Data Set 9OtherFR U-I
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta01121458
Pages
2
Persons
0
Integrity
No Hash Available
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
FR U-I
OMB No. 7100-0115
Approval expires January 31. 2010
BOARD OF GOVERNORS OF THE FEDERAL RESERVE SYSTEM
Statement of Purpose for an Extension of Credit Secured by Margin Stock
(Federal Reserve Form U-1)
JPMorgan Chase Bank, N.A.
Name of Bank
This form is required by law (15 U.S.C. 78g and 78w: 12 CFR 221).
The Federal Reserve may not conduct or sponsor, and an
organization (or a person) is not required to respond to. a collection
of information unless it displays a currently valid OMB control
number.
Public reporting burden for this collection of information is
estimated to average 10 minutes per response. including the time
Instructions
to gather and maintain data in the required form and to review
instructions and complete the information collection.
Send comments regarding this burden estimate or any other
aspect of this collection of information, including suggestions for
reducing this burden to: Secretary. Board of Governors of the
Federal Reserve System. 20th and C Streets. N.W., Washington.
DC 20551: and to the Office of Management and Budget.
Paperwork Reduction Project (7100.0019).Washington, DC 20503.
1. This form must be completed when a bank extends credit in excess of $100,000 secured directly or indirectly. in whole or in
part. by any margin stock.
2. The term "margin stock" is defined in Regulation U (12 CFR 221) and includes. principally: (1) stocks that are
registered on a national securities exchange or any over-the-counter security designated for trading in the National
Market System: (2) debt securities (bonds) that are convertible into margin stocks; and (3) shares of most mutual funds.
3. Please print or type (if space is inadequate. attach separate sheet).
Part I To be completed by borrower(s)
1. What is the amount of the credit being extended? $
2. Will any part of this credit be used to purchase or carry margin stock?
K
Yes K
No
If the answer is "no," describe the specific purpose of the credit.
I (We) have read this form and certify that to the best of my (our) knowledge and belief the information given is true. accurate, and
complete, and that the margin stock and any other securities collateralizing this credit are authentic, genuine. unaltered, and not stolen,
forged. or counterfeit.
Signed: SOUTHERN FINANCIAL, LLC
5/1 5/201 3
Borrower and/or Pledgor's signature
Date
Jeffrey Epstein, Manager
Print or type name
This form should not be signed if blank.
A borrower who falsely certifies the purpose of a credit on this form or otherwise willfully or intentionally evades the
Regulation U will also violate Federal Reserve Regulation X, -Borrowers of Securities Credit."
EFTA01121458
FR U.I
Page 2 of 2
Part II To be completed by bank only if the purpose of the credit is to purchase or carry margin securities (Part 1(2) answered "yes")
1.
List the margin stock securing this credit: do not include debt securities convertible into margin stock. The maximum loan value of
margin stock is 50 per cent of its current market value under the current Supplement to Regulation U.
No. of
Shares
Issue
Market price
per share
Date and source
Total
of valuation
(See note below)
market
Value per issue
2. List the debt securities convertible into margin stock securing this credi . The maximum loan value of such debt securities is 50
ercent of the current market value under the current Supplement to Regulation U.
Principal
amount
Issue
Market price
Date and source
of valuation
(See note below)
Total market
value per issue
3. List other collateral including non-margin stock securing this credit.
Describe briefly
Market price
Date and source
of valuation
(See note below)
Good faith
loan value
Note: Bank need not complete 'Date and source of valuation' if the market value was obtained horn regularly published information in a journal of general circulation or an
automated quotation system.
Part III To be signed by a bank officer in all instances.
I am a duly authorized representative of the bank and understand
that this credit secured by margin stock may be subject to the
credit restrictions of Regulation U. I have read this form and any
attachments. and I have accepted the customer's statement in
Part I in good faith as required by Regulation U': and I certify that
to the best of my knowledge and belief, all the information given
is true. accurate. and complete. I also certify that if any securities
that directly secure the credit are not or will not be registered in
the name of the borrower or its nominee. I have or will cause
Date
Title
to have examined the written consent of the registered owner
to pledge such securities. I further certify that any securities
that have been or will be physically delivered to the bank in
connection with this credit have been or will be examined, that
all validation procedures required by bank policy and the
Securities Exchange Act of 1934 (section 17(f), as amended)
have been or will be performed: and that I am satisfied to the
best of my knowledge and belief that such securities are
genuine and not stolen or forged and their faces have not
been altered.
Signed:
Bank officer's signature
Print or type name
• To accept the customer's statement in good faith. the duly authorized representative of the creditor must be alert to the circumstances surrounding the credit and. it in
possession of any information that would cause a prudent person not to accept the statement without inquiry, must have investigated and be satisfied Mal the statement is
truthful. Among the facts which would require such investigation is receipt of the statement through the mail or from a third party.
This form must be retained by the lender for three years after the credit is extinguished.
EFTA01121459
Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.